What ad­u­canum­ab means for Alzheimer's, un­pack­ing a safe­ty bar­ri­er in CAR-T, the push to up­grade a key ALS tri­al tool, and more

Wel­come back to End­points Week­ly, your re­view of the week’s top bio­phar­ma head­lines. Want this in your in­box every Sat­ur­day morn­ing? Cur­rent End­points read­ers can vis­it their read­er pro­file to add End­points Week­ly. New to End­points? Sign up here.

The team has worked hard to bring you the lat­est up­dates from #AS­CO21 based on ab­stract drops. But there are much more in­sights to be gleaned from the ac­tu­al (vir­tu­al) meet­ing. If you’re in­ter­est­ed in the lat­est land­scape of can­cer drug R&D, don’t miss End­points’ AS­CO event. We’ll start off with a round ta­ble dis­cus­sion among some top in­dus­try ex­perts fol­lowed by an in-depth look at BC­MA and where the lead­ers in the field are head­ed. Learn more and sign up here.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER